1

1	Title: Measuring st	roke outcomes using	g linked administrative	data: Population-based
---	---------------------	---------------------	-------------------------	------------------------

2 estimates and validation of "home-time" as a surrogate measure of functional status.

3		
4	Authors:	
5	Name:	Melina Gattellari ^{*a,b}
6	Email:	melina.gattellari@health.nsw.gov.au
7		
8	Name:	Chris Goumas ^{a,c}
9	Email:	chris.goumas@sydney.edu.au
10		
11	Name:	Bin Jalaludin ^{a,d,e}
12	Email:	bin.jalaludin@health.nsw.gov.au
13		
14	Name:	John Worthington ^{a,b,f}
15	Email:	John.Worthington@health.nsw.gov.au
16		
17	Affiliations:	^a Ingham Institute for Applied Medical Research,
18		1 Campbell Street, Liverpool, NSW, 2170, Australia
19		
20		^b Department of Neurology, Royal Prince Alfred Hospital,
21		Missenden Road, Camperdown, NSW, 2050, Australia.
22		
23		^c School of Public Health, University of Sydney
24		
25		^d Population Health Intelligence, Healthy People and Places Unit; South
26		Western Sydney Local Health District, Liverpool, Sydney, New South
27		Wales, Australia
28		
29		^e School of Public Health, The University of New South Wales,
30		Kensington, Sydney, New South Wales, Australia
31		
32		^f South Western Sydney Clinical School, The University of New South
33		Wales, Liverpool, Sydney, New South Wales, Australia
34		
~ -	*0 1	

35 *Corresponding author.

2

36 Abstract

Background: Administrative data offer cost-effective, whole-of-population stroke
surveillance yet the lack of validated outcomes is a short-coming. The number of days spent
living at home after stroke ("home-time") is a patient-centred outcome that can be objectively
ascertained from administrative data. Population-based validation against both severity and
outcome measures and for all subtypes is lacking.

42 Methods: Stroke hospitalisations from a state-wide census in New South Wales, Australia,

43 from July 1, 2005 to March 31, 2014 were linked to pre-hospital data, post-stroke admissions

44 and deaths. We calculated correlations between 90-day home-time and Glasgow Coma Scale

45 (GCS) scores, measured upon a patient's initial contact with paramedics, and Functional

46 Independence Measure (FIM) scores, measured upon entry to rehabilitation after the acute

- 47 hospital stroke admission. Negative binomial regression models were used to identify
- 48 predictors of home-time.

49 Results: Patients with stroke (N=74,501) spent a median of 53 days living at home after the 50 event. Median home-time was 60 days after ischaemic stroke, 49 days after subarachnoid 51 haemorrhage and 0 days after intracerebral haemorrhage. GCS and FIM scores significantly 52 correlated with home-time (p-values<0.001). Female sex predicted less home-time in 53 ischaemic stroke, while being married increased home time after ischaemic stroke and 54 subarachnoid haemorrhage.

55 Conclusions: Home-time measured using administrative data is a robust, replicable and valid
56 patient-centred outcome enabling inexpensive population-based surveillance.

57 Keywords: Stroke, outcomes, administrative data, validation, disability, epidemiology

58 List of Abbreviations: IS:Ischaemic stroke; ICH: Intracerebral haemorrhage; SAH:

59 Subarachnoid haemorrhage; NIHSS: National Institutes of Health Stroke Scale; FIM:

- 60 Functional Independence Measure; GCS: Glasgow Coma Scale; NSW: New South Wales;
- 61 eMR: electronic Medical Records (Ambulance NSW); PHCR: Patient Health Care Record
- 62 (Ambulance NSW).

4

63 **1. Introduction**

Stroke is a leading cause of death and disability with significant global disparities in 64 incidence, mortality and morbidity [1]. Over the past two decades there have been 65 considerable advances in primary and secondary stroke prevention, particularly in high-66 income nations [2-5] and, more recently, health services have been re-designed in several 67 68 countries to facilitate access to multidisciplinary stroke unit care, thrombolysis and mechanical thrombectomy for ischaemic stroke and endovascular coiling for subarachnoid 69 haemorrhage [6-9]. Monitoring stroke outcomes can assist in identifying areas of need, 70 informing implementation strategies to bridge evidence-practice gaps. Administrative data 71 offer a cost-effective alternative to labour-intensive gold-standard epidemiological studies, 72 providing whole-of-population stroke surveillance [10]. However, the absence of validated 73 outcomes after stroke is a significant shortcoming. 74

Home-time measures the number of days spent at home after stroke onset, taking into account 75 76 patient survival and days spent in hospital, reflecting a patient's capacity to return to their private residence after hospitalisation [11-15]. Home-time therefore can be unobtrusively and 77 objectively measured using routinely collected data that are linked to health records following 78 stroke and is proposed as a patient-centred surrogate measure of functional status. Unlike 79 80 traditional stroke outcome measures, such as the modified Rankin Scale, the validity of 81 home-time is not threatened by inter-rater variability, attrition of research participants or 82 respondent characteristics (proxy versus patient) [16,17]. Home-time derived from administrative data may therefore be a cost-effective adjunct to traditional patient reported 83 84 outcomes to minimise selection bias, improve the reliability of outcome assessment and allow continuous large-scale monitoring that otherwise would be impracticable. Deriving home-85 time from administrative data may also broaden patient representation in epidemiological and 86 health services research. For example, patients whose preferred language is not the dominant 87

5

community language or those with cognitive impairment may encounter barriers to effective
engagement in research and quality assurance activities. Characterised in this way, hometime is inclusive, ascertained for all patients irrespective of their socio-demographic and
health characteristics.

Few studies validating home-time are population-based or have validated home-time against both severity and outcome measures and for all stroke sub-types [11,14]. Further, there is limited information about prognostic indicators of home-time and validation has yet to be conducted where severity, home-time and functional status are measured wholly using routinely collected data. We analysed a jurisdiction-wide analysis reporting population-based estimates of home-time and validated home-time as an outcome measure for routine stroke surveillance.

99 **2. Methods**

Reporting according to the "**RE**porting of studies Conducted using **O**bservational **R**outinelycollected health **D**ata (RECORD) Statement" is reported in Supplementary Table 1.

2.1 Patient Selection: The study was part of the Home to Outcomes (H₂0) project which 102 103 aimed to report stroke epidemiology and outcomes in New South Wales (NSW), Australia's most populous state (population ~7.99 million in 2019). The project utilised linked routinely 104 collected pre-hospital, hospital, rehabilitation and mortality data. As previously described 105 [18,19] deterministic and probabilistic linkages were performed by the Centre for Health 106 Record Linkage (CHeReL) using gold-standard privacy preserving protocols and ensuring 107 that the linkage error rate was no greater than 5 per 1,000. Patient identifiers, such as names, 108 addresses, dates of birth and dates of health service delivery (for example, dates of 109 admission) facilitated linkage. Quality assurance of the linkage process undertaken by the 110 CHeReL has been described (http://www.cherel.org.au/quality-assurance). 111

6

Patients over the age of 15 years were identified from the Admitted Patient Data Collection, a 112 census of all hospital separations in NSW recording the principal diagnosis and up to 49 113 secondary diagnoses using the International Classification of Diseases, version 10, Australian 114 Modification (ICD-10AM) [20]. Applying ICD-10AM codes recommended to assign stroke 115 sub-types [21,22], we selected admissions with a principal diagnosis of subarachnoid 116 117 haemorrhage (ICD-10AM I60), intracerebral haemorrhage (ICD-10AM I61, I62.9) and 118 ischaemic stroke (ICS-10AM I63, I64) from January1, 2005 to March 31st, 2014 providing a minimum follow-up of 90-days to June 30, 2014, the most recently available data at the time 119 120 linkage was performed. Strokes recorded in secondary diagnostic positions were included if the primary diagnosis indicated an acute stroke event, where iatrogenic causes were identified 121 or where the stroke was flagged as occurring in hospital. Where primary diagnoses indicated 122 I64 or I62.9 codes (unspecified stroke and unspecified haemorrhagic stroke, respectively), we 123 interrogated records for more specific stroke codes to assign stroke-subtype. Sub-type was 124 defined in this manner for 2,417 or 2.5% of cases; otherwise, we adhered to 125 recommendations to code these cases as ischaemic stroke (that is, I64) [21] or intracerebral 126 haemorrhage (that is, I62.9) [22]. 127 As previously reported [18,19], patients where ineligible if resident outside NSW or if cases 128 had concomitantly recorded major head trauma (ICD-10AM S04, S06, S07, S08, S17, S18, 129 130 S01.7, S02.0, S02.1, S02.6, S02.7, S03.0, S09.0, S09.2, S09, S05.2, S05.7) or primary or metastatic cerebral neoplasms (C71,C70.0,C70.9, C79.3,D33.0, D33.1, D33.2, D33.3, 131 D33.9). We excluded cases whose initial stroke diagnosis was revised upon transfer to 132 another hospital by the end of the next day after presentation as presumed misclassified cases. 133 Early discharges home, defined as completion of care allowing discharge within the first 48 134 hours, were excluded to increase the specificity of case ascertainment consistent with 135

136 previous approaches [23-25] and remove patients with early symptom resolution suggesting

7

transient ischaemic attack or stroke mimics and cases with unrevised provisional stroke
diagnoses. Patients transferred for care outside the state and other transfers in the absence of
contiguous records were also excluded as missing hospitalisation data precluded accurate
calculation of home-time. The first eligible stroke admission ("index admission") for each
patient during the study period was selected for analysis.

2.2 Calculation of 90-day home-time: In keeping with other research [14], home-time was 142 143 defined as the sum of full days not spent in hospital in the 90 days after the stroke admission. For patients dying or newly discharged to a nursing home within 90-days, zero days were 144 145 counted from the date of death or discharge, respectively. Ninety-day "home-time" was calculated by linking stroke cases to subsequent hospital records and the state death register 146 to June 30, 2014. Hospital records incorporated the acute stroke admission including inter-147 hospital transfers, any contiguously recorded in-patient rehabilitation following the acute 148 period of stay and all subsequent acute and sub-acute readmissions for any reason, including 149 rehabilitation. Hospital encounters also included same-day admissions, which included out-150 patient rehabilitation. 151

Prior to applying eligibility and exclusion criteria, we undertook data cleaning for cases with 152 illogical death record data to facilitate valid calculation of 90-day home-time. Specifically, 153 there were 70 death records with duplicate records indicating more than one probable linkage 154 155 to mortality data. We selected the record with information consistent with data recorded in the other available linked data-sets (for example, consistent age and sex between death and 156 admissions records). There were a further 38 records with dates of death preceding hospital 157 discharge by more than one day. Of these, eleven were deemed clerical errors and accepted as 158 valid, while the remaining were considered erroneously linked death records. 159

160 **2.3 Measures validating home-time**

8

161 **2.31 Proxy stroke severity measurement**

As described previously [19], we developed a proxy measure of stroke severity incorporating 162 the Glasgow Coma Scale (GCS) and mode of arrival (ambulance or private transport) by 163 linking admissions to pre-hospital data obtained from Ambulance NSW, the sole provider of 164 emergency services for the state. Total GCS scores were obtained from the initial pre-hospital 165 166 vital signs survey recorded at first contact with paramedics. Pre-determined cut-offs categorised patients as fully alert with a maximum score of 15 or with mild, moderate or 167 severe levels of lowered consciousness [26,27]. Self-presenting patients arriving to hospital 168 by private transport were considered "ambulant". Both arrival mode and GCS were near 169 universally available, measured prospectively at first contact with health services and 170 ascertained blinded to patient outcomes. The GCS and mode of arrival strongly predict stroke 171 mortality [26-29], providing de-facto validity for the composite measure. Within the H₂0 172 study cohort, we have published a validation of the proxy severity measure in ischaemic 173 174 stroke (N>17,000 patients) demonstrating a strong association with 30-day mortality with cross-validation of findings (N>18,000 patients) [19]. 175

2.32 Functional Status: We obtained the 18-item Functional Independence Measure (FIM) 176 [30] from the NSW Subacute and Non-Acute Data Collection, recorded upon patient's first 177 admission to inpatient rehabilitation within 90-days of the stroke admission. FIM scores were 178 179 available from July 1, 2009 for the sub-set of publicly funded hospitals, which provided ~70% of inpatient stroke rehabilitation in Australia during the study period [31]. The FIM 180 comprises 19 items, with 13 measuring motor function and five measuring cognitive function. 181 182 Each item was measured using a seven-point ordinal scale with higher scores indicating greater independence with everyday tasks, such as mobility, eating, bathing, memory and 183 problem solving. Total scores ranged from 18 to 126, while motor and cognitive subscale 184 scores ranged from 13 to 91 and 5 to 35, respectively. 185

9

2.4 Statistical analysis: As home-time had a skewed distribution, we report median values 186 and the interquartile range (IQR) for all strokes and by stroke sub-type. Mean values (\pm 187 Standard Deviation) were calculated to enable comparisons with other studies. We calculated 188 Spearman correlations between home-time and GCS and FIM scores. These descriptive 189 analyses were repeated excluding patients dying in hospital who, by definition, spent zero 190 days at home. We also report mean and median values for "home-time" for each level of the 191 192 proxy stroke severity measure incorporating the GCS categories and mode of arrival. To identify predictors of home-time, multivariate negative binomial regression was carried 193 out to take into account the skewed distribution of home-time and its measurement in counts 194 of whole days. We used generalised estimation equations to account for inter-dependencies of 195 data clustered on hospital of presentation. Modelling was carried out using PROC GENMOD 196 (SAS 9.4, SAS institute Inc, Cary, USA) and an exchangeable working correlation. Adjusted 197 means were derived from the model output. Potential predictors included age, sex, year of 198 199 admission, marital status and our proxy stroke severity measure. In addition, we ascertained stroke history and Charlson comorbidities via linkage to prior hospitalisations up to July 1, 200 2001, providing 4.5 years of historical admissions data for all cases. To allow for departure 201 202 from linearity, we included both linear and quadratic terms for age and modelled each Charlson comorbidity characterised by applying ICD-10 codes as reported by Quan, 203 204 Sundararjan, Halfon et al [32]. Hemiplegia and cerebrovascular disease were removed as redundant [33] while the effect of HIV/AIDs was not assessed given its very low prevalence. 205 We modelled a measure of socio-economic status, the Index of Relative Socio-economic 206 Disadvantage (IRSD) [34] reflecting the degree of disadvantage within the geographical area 207 of patient residence based on area-aggregated indicators such as income, educational status 208

and occupation collected from a mandatory, national census carried out once every five years

210 (>95% participation rate of eligible households) [35]. IRSD scores are categorised into

211	quintile cut-offs with lower scores indicating greater relative disadvantage. Multivariate
212	analyses also adjusted for the length of time patients spent in hospital in the twelve-months
213	prior to the stroke admission to account for pre-existing comorbidity burden and health
214	service utilisation proximal to the stroke event. Analyses were undertaken separately for each
215	of the individual stroke sub-types given the well-established differences in patient
216	characteristics, risk factors and prognosis. All analyses were carried out using SAS software
217	(SAS 9.4, SAS institute Inc, Cary, USA).
218	2.5 Ethics
219	The NSW Population and Health Services Ethics Committee approved the study
220	(HREC/14/CIPHS/17).
221	3. Results
222	3.1 Patient selection and characteristics: Of the 83,866 potentially eligible stroke
223	admissions amongst NSW residents, there were 80,365 (95.8%) cases without known missing
224	home-time data. Of these, 74,501 were index admissions including 57,949 patients with
225	ischaemic stroke (77.8%), 12,192 with intracerebral haemorrhage (16.4%) and 4,360 with
226	subarachnoid haemorrhage (5.9%) for which home-time was calculated (Figure 1). Almost
227	half were female (N=37,097; 49.8%). One in four patients were older than 85 years of age
228	(24.6%), while 7.0% were younger than 50 years (Supplementary Table 1).



258 Figure 1: Linkage and patient selection flow chart.

12

259	3.2 Descriptive analysis of home-time estimates: Median home-time in the 90-days after
260	stroke was 53 days (IQR=0 to 80 days). Median home-time was longer after an ischaemic
261	stroke (Median=60-days; IQR=0 to 81) and shortest after an intracerebral haemorrhage
262	(Median=0 days; IQR=0 to 63). Median home-time after a subarachnoid haemorrhage was
263	49 days (IQR=0 to 80 days). Almost 20% of patients (N=25,987) spent zero days at home in
264	the 90-days after stroke. Just under one-third of ischaemic stroke patients (N=17,575; 30.3%)
265	did not spend any full days at home compared with 55.2% (N=6,731) with intracerebral
266	haemorrhage and 38.6% (N=1,681) with subarachnoid haemorrhage. When the study
267	population was restricted to the sub-set of patients who survived their stroke admission, the
268	estimated median home-time was similar for patients with ischaemic stroke and subarachnoid
269	haemorrhage (Median=70 days and 69 days, respectively) and lower for those with an
270	intracerebral haemorrhage (Median=55 days (IQR=5 to 78) (Table 1).
271	3.2.1 Descriptive statistics for home-time according to age and sex Median home-time was
272	15 days longer for males compared with females after an ischaemic stroke and nine days
273	longer for men after a subarachnoid haemorrhage (Table 1). While the median home-time
274	value for intracerebral haemorrhage was zero days for both sexes, the 75 th percentile value for
275	home-time was 67 days for men and 59 days for women. When restricted to patients who
276	survived their stroke admission at discharge, median values for males remained higher for all
277	subtypes although differences were attenuated.
278	Increasing age was associated with a reduction in home-time for all sub-types. The decrease
279	in median time across age was relatively gradual after ischaemic stroke ranging from 80 days

in patients younger than 50 years of age to 56 days in those aged 75 to 84 years. Home-time

reduced to zero days in patients older than 85 years. After intracerebral haemorrhage, median

home-time decreased from 54 days in patients younger than 50 to 40 days in those aged 50-

283 64 and then eight days in patients aged 65 to 74 years. After subarachnoid haemorrhage,

- median home-time decreased from 69 days in patients younger than 50 to 25 days in those
- aged 65-74 years. In both haemorrhagic stroke subtypes, median home-time was zero for
- 286 patients older than 75 years.

14

	All ca	ises		Excluding in-hospital deatl		al deaths
Sub-type	Ν	Mean (±SD)	Median (IQR)	Ν	Mean (±SD)	Median (IQR)
Sub-type						
IS	57,949	47±36	60 (0-81)	48,153	56±32	70 (33-83
ICH	12,192	27±34	0 (0-63)	7,147	46±33	55 (5-78)
SAH	4,360	40±35	49 (0-74)	3,082	56 ± 28	69 (41-77
Total	74,501	43±36	53 (0-80)	58,382	55±32	69 (30-82
Subtype by sex						
IS						
Male	29,653	51±35	66 (0-82)	25,431	59±31	74 (41-83
Female	28,296	42±36	51 (0-80)	22,722	53±33	66 (21-82
ICH						
Male	6,059	29±35	0 (0-67)	3,670	48±33	57 (12-80
Female	6,133	25±33	0 (0-59)	3,477	43±33	52 (0-76
SAH						
Male	1,692	42±35	55 (0-76)	1,237	58 ± 28	70 (43-78
Female	2,668	38±35	46 (0-73)	1,845	55±29	68 (38-76
Subtype by age						
< 50 years	2 925	66+28	80 (60-85)	2 777	70+24	80 (67-85
< 50 years $50-64$ years	2,725 8 348	62+31	78 (46-84)	2,777	70±2 4 66+27	79 (57-85
65-74 years	11 668	55+33	72 (26-83)	10 505	62+29	76 (47-84
75-84 years	19 870	45+35	56 (0-80)	16,505	54+32	67 (28-82
85+ years	15,138	30±35	0 (0-67)	10,625	43±34	52 (0-76)
ICH						
<50 years	967	44±36	54 (0-79)	765	56±31	69 (35-82
50-64 years	1,796	39±36	40 (0-78)	1,282	54±31	66 (28-82
65-74 years	2,350	32±35	8 (0-69)	1,499	49±32	58 (17-81
75-84years	4,205	23±32	0 (0-53)	2,277	43±33	49 (0-74)
85+ years	2,874	17±29	0 (0-28)	1,324	36±33	38 (0-68
SAH						
<50 years	1,313	53±32	69 (25-77)	1,122	62±25	72 (56-78
50-64 years	1,376	46±34	63 (0-75)	1,096	58±27	69 (48-76
65-74 years	674	34±34	25 (0-69)	448	50±30	61 (25-76
75-84 years	656	21±31	0 (0-48)	311	44±31	51 (6-74
85+ years	341	11±26	0 (0-0)	105	37±35	39 (0-73

Table 1. Descriptive statistics for days at home "home-time" within 90 days of diagnosis by sex and age

290 IS=Ischaemic Stroke

291 ICH=Intracerebral Haemorrhage

292 SAH=Subarachnoid Haemorrhage

15

293 **3.3 Validity of home-time**

294 3.31 Association between home-time and proxy severity measure

295 Amongst self-presenting "ambulant" patients who did not require paramedic transport, the median home-time was 76 days (IQR=39-84) after ischaemic stroke, 53 days (IQR=0 to 81 296 days) after intracerebral haemorrhage and 70 days (IQR=28 to 78) after subarachnoid 297 haemorrhage. GCS scores were available for 48,597 out of 49,150 (98.9%) patients 298 transported via ambulance. After either an intracerebral or subarachnoid haemorrhage, 299 300 median home-time was zero for patients with any decreased level of consciousness (GCS scores less than 15) (Table 1). Median home-time was zero after ischaemic stroke in patients 301 with GCS scores less than 13. Amongst patients surviving their stroke admission, home-time 302 303 decreased with decreasing levels of consciousness. However, in patients with haemorrhagic 304 stroke, median home-time was higher for patients whose GCS scores indicated "very severe"

brain injury (that is, unconscious patients), than for those with "severe" brain injury.

306 3.32 Home-time and GCS and FIM scores

307 Higher GCS scores indicating higher levels of consciousness were moderately and

308 significantly correlated with more home-time in ischaemic stroke and intracerebral

haemorrhage (rho=0.35 and rho=0.39) (p<0.001) (Table 3). GCS scores more strongly

310 correlated with home-time in subarachnoid haemorrhage (rho=0.51) (p<0.001). The

311 correlation between GCS scores and home-time remained significant in the sub-group of

312 patients who survived their stroke admission; however, the association was reduced (Table

313 3).

16

316 by sex and t	*9v	Overa	all	Excluding in	-hospital death	IS
	Ν	Mean±SD	Median (IQR)	N	Mean±SD	Median (IQR)
IS						
Ambulant	20,407	59±32	76 (39-84)	18,443	65±27	78 (56-84)
GCS=15	21,735	50±34	63 (1-81)	19,190	56±31	69 (36-82)
GCS=13-14	7,209	35±35	28 (0-73)	5,812	44±34	52 (0-77)
GCS=9-12	5,652	22±32	0 (0-51)	3,532	36±34	32 (0-70)
GCS=3-8	2,507	11±25	0 (0-0)	866	33±33	23 (0-67)
ICH						
Ambulant	3,344	43±37	53 (0-81)	2,489	58±31	72 (39-83)
GCS=15	3,694	33±34	23 (0-68)	2,638	46±32	53 (9-76)
GCS=13-14	1,792	22±31	0 (0-50)	1,101	37±32	40 (0-66)
GCS=9-12	1,567	11 ± 24	0 (0-0)	640	27±31	12 (0-55)
GCS=3-8	1,708	4±16	0 (0-0)	235	30±33	15 (0-62)
SAH						
Ambulant	1,600	54±32	70 (28-78)	1,351	64±24	73 (61-80)
GCS=15	1,297	48±32	64 (4-75)	1,087	57±27	68 (45-76)
GCS=13-14	392	29±33	0 (0-65)	260	43±31	52 (0-73)
GCS=7-12	459	16±26	0 (0-28)	226	33±30	28 (0-62)
GCS=3-6	585	8±21	0 (0-0)	145	33±30	34 (0-63)

Table 2: Descriptive statistics for days at home "home-time" within 90 days of diagnosis by sex and age

317 IS=Ischaemic Stroke

318 ICH=Intracerebral Haemorrhage

319 SAH=Subarachnoid Haemorrhage

17

320	Table 3: Spearman	correlation (rho)) between	GCS and	FIM scores and
-----	-------------------	-------------------	-----------	---------	----------------

321 "Home-Time"

	0	verall	Excluding in-hospital deaths	
Sub-type	Ν	Rho	Ň	Rho
GCS scores				
IS	37,103	0.35	29,400	0.24
ICH	8,761	0.39	4,614	0.21
SAH	2,733	0.51	1,718	0.34
FIM scores				
Motor subscale				
IS	6,751	0.64	6,608	0.64
ICH	1,253	0.62	1,229	0.63
SAH	349	0.68	346	0.68
Cognitive subscale				
IS	6,751	0.43	6,608	0.42
ICH	1,253	0.36	1,229	0.36
SAH	349	0.47	346	0.47
Total FIM score				
IS	6,751	0.66	6,608	0.65
ICH	1,253	0.63	1,229	0.63
SAH	349	0.69	346	0.69

324 IS=Ischaemic Stroke

325 ICH=Intracerebral Haemorrhage

326 SAH=Subarachnoid Haemorrhage

327 All Spearman rho-values were statistically significant (p-values<0.001).

18

333	3.4 Predictors of home-time
332	were largely unchanged when restricted to patients surviving their stroke admission.
331	cognitive scores ($r_{values}=0.62$ to 0.68 versus $r_{values}=0.36-0.47$) (p-values<0.001) (Table 3) and
330	to 0.69) (p-values<0.001). Motor scores were more strongly correlated with home-time than
329	in-patient rehabilitation. FIM scores correlated with home-time for all sub-types (r_{values} =0.63
328	FIM scores were available from 2009 onwards for 8,353 patients undergoing publicly funded

334 Increasing stroke severity assessed using our proxy composite measure independently

335 predicted fewer days spent at home after stroke for all subtypes in multivariate analyses (p-

values<0.001) (Figure 2; Supplementary Tables 2-5).

337 Amongst ischaemic stroke patients, married patients spent significantly more days at home

than single patients (Adjusted mean values=43 versus 39 days) (p<0.001) (Supplementary

Table 3). The effect of socio-economic status was near significant (p=0.05). Patients

340 residing in areas of least socio-economic disadvantage spent the greatest number of days at

home (42 days) although differences in adjusted means between categories were small (one

to two days). Home-time was reduced in the presence of all Charlson comorbidities tested,

343 except connective tissue disease. Dementia (31 versus 41 days), metastatic malignancy (27

versus 41 days) and moderate or severe liver disease (30 versus 41 days) had the greatest

345 impact on home time after ischaemic stroke. The adjusted effect of sex was significant

346 (p=0.02). While adjusted mean home-time values for males and females were equivalent (41

days) the confidence intervals suggesting a higher range of estimated values for males (95%

348 CI=41-42 versus 95% CI=40 to 41).



- 352 SAH=Subarachnoid haemorrhage
- 353

349 350

351

354 Figure 2: Adjusted Mean Home-time by stroke severity category

20

After intracerebral haemorrhage, patients spent significantly less time at home if they had a 355 documented diagnosis of myocardial infarction (18 versus 21 days), congestive heart failure 356 (17 versus 21 days), peripheral vascular disease (18 versus 21 days), renal disease (18 versus 357 21) and non-metastatic malignancy (17 versus 21 days). Patients with uncomplicated diabetes 358 spent more time at home (23 versus 20 days) (Supplementary Table 4). Patients with 359 subarachnoid haemorrhage spent significantly more time at home if they were married (32 360 361 versus 28 days) or if they had a previous stroke (40 versus 30 days) (p=0.02). The history of renal disease and moderate or severe liver disease were associated with less home-time after 362 363 stroke (23 versus 31 days, p=0.03; 16 versus 31 days, p=0.03, respectively) (Supplementary Table 5). There was significant variation in home-time estimates according to year of 364 admission for all sub-types, however, no clear linear association was evident. 365

366 4. Discussion

367 **4.1 Main findings:**

Home-time was reduced with increasing age, more severe disease and after intracerebral and
subarachnoid haemorrhage, all of which are known to adversely affect stroke outcome. Less
functional independence and greater comorbidity burden also reduced home-time. These
findings underscore the immediate adverse impact of stroke on people's ability to live at
home after the event and provide further evidence that home-time serves as a useful proxy for
disability.

The large cohort afforded reliable insights into the impact of stroke in relatively young patients of which there were 5,205 cases aged younger than 50 years. Younger patients with intracerebral and subarachnoid haemorrhage spent less time at home compared with patients older than 75 after an ischaemic stroke. More than half of patients over the age 75 years after haemorrhagic stroke and half of those older than 85 years after an ischaemic stroke did not

21

379 spend any time at home highlighting the considerable burden of stroke affecting elderly380 members of the community.

381 Females with ischaemic stroke spent fewer days at home as reported elsewhere [11,36]. While sex differences either narrowed or did not persist in multivariate analyses accounting 382 for age, these findings demonstrate women's vulnerability to poor outcomes due to their 383 384 relatively advanced age, consistent with results from gold-standard incident stroke studies [37]. Patients residing in areas of greater socio-economic disadvantage and single patients 385 with ischaemic stroke or subarachnoid haemorrhage had lower home-time estimates. Socio-386 demographic characteristics have also been associated with traditional stroke outcome 387 measures [38]. These results either implicate patient characteristics in post-stroke morbidity 388 or, alternatively, indicate that home-time measures constructs other than disability. For 389 example, socio-demographic variables, may mediate their accessibility to health services 390 post-stroke. 391

These findings inform the validity of the composite surrogate severity measure incorporating GCS and mode of arrival. The association between GCS and home-time was strongest for subarachnoid haemorrhage corroborating GCS as a valid component of standardised severity measures for this sub-type [27]. The correlation between GCS and home-time attenuated when in-patient deaths were removed from the cohort consistent with patterns of correlations reported when using gold-standard stroke severity assessment [14].

Previous results demonstrate that home-time correlates with the modified Rankin Scale or the Barthel Index [11-15,36,39]. Here, we demonstrate a strong correlation with another measure of functional status, the FIM, adding weight to the construct validity of home-time. Total FIM and motor subscale scores were strongly associated with home-time, while the correlation between cognitive subscale scores and days spent at home was more moderate.

22

Home-time may therefore underestimate disability due to cognitive deficits, a shortcoming
shared with traditional stroke outcome measures, such as the modified Rankin Scale score
[40].

4.2 Comparison with previous work: Two other population-based studies have published 406 home-time estimates [11,14]. A nation-wide Scottish study of over 101,000 patients defined 407 408 home-time as we have done and reported estimates comparable to those observed here [14]. Home-time was not reported separately for haemorrhagic and ischaemic stroke and the gold-409 standard NIHSS severity measure was ascertained in around 5% of cases. Standardised 410 outcome measures were unavailable. Another study identified ~15,000 stroke cases 411 representing all subtypes as here and counted overnight hospital stays only [11]. Validation of 412 home-time was carried out for 552 patients with ischaemic stroke for whom the modified 413 Rankin Scale scores were available. 414

In a multi-centre study of 1,866 subarachnoid haemorrhage patients with gold-standard case ascertainment, readmission data were not available [12]. Home-time strongly correlated with the modified Rankin Scale. Our results strengthen evidence for the validity of home-time in subarachnoid haemorrhage with more robust home-time assessment.

4.3 Strengths and limitations: Strengths include cost-effective, near universal home-time
and proxy severity ascertainment, and population-based validation of home-time against
baseline and outcome measures for all stroke sub-types with granular reporting of home-time
by patient characteristics. Another strength was the capacity to capture same-day admissions
including out-patient rehabilitation offered by hospitals and short-stay admissions as ignoring
these admissions will artificially inflate home-time for patients with residual, ongoing
disability.

23

Coding inaccuracy is a potential limitation although accuracy is often high [21]. As 426 previously discussed [18], stroke coding in Australia has been validated in several studies 427 showing high levels of accuracy in terms of positive predictive value, inter-rater coder 428 reliability and sensitivity. Comorbidities are only coded if these require treatment in hospital 429 and therefore it is likely comorbidities were under-numerated, although applying a look-back 430 period reduces under-numeration [41]. The apparent protective effects of stroke history in 431 432 subarachnoid haemorrhage and uncomplicated diabetes in intracerebral haemorrhage may reflect less severe aetiology (for example, non-aneurysmal aetiology for subarachnoid 433 434 haemorrhage) or differential ascertainment of comorbidities in patients with dissimilar prognoses. Specifically, under-ascertainment may be more likely in patients who die within 435 hours of admission or who are acutely unwell as the management of chronic comorbidities is 436 not central to the care of critically ill patients. In contrast, comorbidities are relevant to 437 relatively well patients and may be preferentially recorded in surviving patients. 438 FIM scores were obtained from in-patient rehabilitation records for the sub-group of patients 439 receiving publicly funded rehabilitation who, by definition, had disability. These results may 440 not generalise to patients undergoing rehabilitation as an outpatient or at private facilities. 441 Home-time was not calculated for the 4.2% of patients either residing or transferred interstate 442 or for those with missing hospitalisation data, and the impact of this source of missing data 443 444 could not be assessed here. Anticipated national data linkage may eliminate shortcomings associated with cross-jurisdictional patient flows [42] while improved data quality will 445 mitigate against data loss. We could not identify cases entering residential care who later 446 returned to a private residence or patients admitted to supported care facilities after discharge 447 to home, although the short 90-day follow-up period may have minimised such 448 misclassification. We did not assess stroke severity using gold-standard measures as these are 449 not available using administrative data, although the GCS is integral to measuring severity in 450

24

451 subarachnoid haemorrhage [27] and is strongly predictive of mortality for ischaemic stoke452 [19, 26] and intracerebral haemorrhage [26].

453 Loss of consciousness may be an inexact proxy for severity. Very low GCS at first point of contact may indicate temporary loss of consciousness due to syncope or seizure, rather than 454 stroke severity. This may account for the higher home-time estimates observed in 455 456 haemorrhagic stroke patients – only in those surviving their admission – whose initial GCS scores fell within the most severe range compared with those whose scores were within the 457 penultimate severity category. While GCS and mode of arrival predict mortality after stroke, 458 the GCS is a weaker correlate of home-time than the National Institutes of Health Stroke 459 Scale (NIHSS) [14], likely reflecting its less sensitive assessment of neurological deficits. 460

4.4 Implications for future research: Definitions of home-time have been adapted to suit 461 462 the scope of administrative data sources at hand. For example, here and previously [14], home-time was defined as the number of full days not spent in hospital while others have 463 464 calculated home-time as the number of nights spent at home [11]. Where available, residential care data provide reliable information about supportive care arrangements [11] 465 whereas we and others [14] relied on hospital disposition coding to identify residential care 466 admissions. Efforts are needed to harmonise the definition of home-time to aid multicentre 467 and multinational studies and comparisons. 468

As noted by others [15], home-time may not accurately reflect disability for patients who receive assistance in their private residence nor does it differentiate between patients according to the level of support required in residential care. Patients discharged home who then die during the follow-up period may have equivalent home-time values as those who survive to 90-days with lengthy in-hospital stays. Further, discharge to nursing home care, death during the stroke admission and hospitalisation for the entire follow-up period yield

25

equivalent home-time estimates of zero days. Whether the validity of home-time can be
improved by adding qualitative information to achieve a more nuanced disability measure
merits future research. Large differences in median values between the main cohort and the
sub-set of patients surviving their stroke admission highlights the sizeable influence deaths
have on home-time estimates. For this reason, we and others report descriptive analyses
excluding in-patient deaths.

481 4.5 Conclusion: In conclusion, these findings support home-time ascertained using
482 administrative data as a robust, inexpensive, replicable and valid patient-centred outcome that
483 facilitates population-based stroke surveillance.

484 Acknowledgements: We thank the Centre for Health Record Linkage, for data linkage
485 services and the NSW Ministry of Health and Ambulance NSW for supplying data for these
486 analyses.

Funding: This work was supported by the New South Wales Ministry of Health, Office for
Health and Medical Research, New South Wales Neurological Conditions Translational
Research Grants Program NSW Neurological Conditions Translational Research Grants
Program. The study sponsor had no role in the study design, in the collection, analysis and
interpretation of data, in the writing of the report and in the decision to submit the article for
publication.

493 Declaration of Interests: JW serves as a Board Member, NSW Ministry of Health, Bureau
494 of Health Information. The Bureau of Health Information utilises linked and unlinked
495 routinely collected health data to evaluate patient outcomes in NSW hospitals. JW was a paid
496 consultant for the Agency for Clinical Innovation, NSW Ministry of Health (2014-2016) to
497 lead a project to reduce unwarranted clinical variation in stroke across the NSW Health
498 Service.

499	Data s	statement: Data analysed as part of this study are third-party owned. Signed				
500	agreements between the researchers and data custodians preclude sharing of individual level					
501	data in	adherence to ethical and legal restrictions that apply to the use of these data-sets.				
502	Reque	sts to access these third-party owned data-sets by qualified researchers can be directed				
503	to the	Centre for Health Record Linkage (<u>www.cherel.org.au</u>). Requests for the programming				
504	code c	an be directed to the corresponding author.				
505	Refere	ences:				
506	1.	Global Burden of Disease Collaborators. Global, regional, and national burden of				
507		stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study				
508		2016. Lancet Neurology, 2019;18:439-58. http://dx.doi.org/10.1016/S1474-				
509		4422(19)30034-1.				
510	2.	NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in				
511		hypertension awareness, treatment, and control in 12 high-income countries: an				
512		analysis of 123 nationally representative survey. Lancet, 2019;				
513		http://dx.doi.org/10.1016/S0140-6736(19)31145-6				
514	3.	Sluggett JK, Caughey GE, Ward MB, Gilbert AL. Use of secondary stroke prevention				
515		medicines in Australia: national trends, 2003-2009. Medical Journal of Australia				
516		2014; 201:54-57. doi:10.5694/mja13.00186				
517	4.	Marshall IJ, Wang Y, McKevitt C, Rudd AG, Wolfe CDA. Trends in risk factor				
518		prevalence and management before first stroke. Data from the South London Stroke				
519		Register 1995-2011. Stroke 2013;44:1809-1816.				
520	5.	Bergström L, Irewall AL, Söderström L, Ögren J, Laurell K, Mooe T. One-year				
521		incidence, time trends and predictors of recurrent ischaemic stroke in Sweden from				
522		1998 to 2010. An observational study. Stroke, 2017; 48"2046-2051.				
523		https://doi.org/10.1161/STROKEAHA.117.016815				

6:

524	6.	Opeolu A, Nyström KV, Yavagal DR, Luciano J, Nogueira RG, Zorowitz RD,
525		KHalessi AA, Bushness C, Barsan WG, Panagos P, Alberts MJ, Tiner C, Schwamm
526		LH, Jauch EC. Recommendations for the establishment of stroke systems of care: A
527		2019 Update. Stroke, 2019;50:e187-e210.
528		https://doi.org/10.1161/STR.000000000000173
529	7.	Campbell BCV. Advances in stroke medicine. 2019;210:doi:10.5694/mja2.50137
530	8.	Norrving B, Barrick J, Davalos A, Dichgan M, Cordonnier C, Guekht A, Kutluk K,
531		Mikulik R, Wardlaw J, Richard E, Nabav D, Molina C, Bath PM, Sunnerhagen KS,
532		Rudd A, Drummond A, PLanas A, Caso V. Action plan for stroke in Europe 2018-
533		2030. European Stroke Journal, 2018; 3:309-336.
534	9.	Connolly ES, Rabinstein AA, Carhuapoma R, Derdeyn CP, Dion J, Higashida RT,
535		Hoh BL, Kirkness CJ, Naidech AM, Ogilby CS, Patel AB, Thompson G, Vespa P.
536		Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke.
537		2012;43:1711-1737.
538	10	. Kleindorfer, D. The bad news. Stroke incidence is stable. Lancet Neurology, 2007; 6
539		470-471. DOI:10.1016/S1474-4422(07)70111-4

- 540 11. Yu AYX, Rogers E, Wang M, Sajobi TT, Coutts SB, et al. Population-based study of
 541 home-time by stroke type and correlation with modified Rankin Score. Neurology,
 542 2017;89:1970-1976. DOI:https:/doi.org/10.1212/WNL00000000004631.
- 543 12. Stienen MN, Smoll NR, Fung C, Goldberg J, Bervini D, et al. Home-time as a surrogate
 544 marker for functional outcome after aneurysmal subarachnoid haemorrhage. Stroke
 545 2018;49:3081-3084. DOI:10.1161STROKEAHA.118.022808.
- J3. Quinn TJ, Dawson J, Lees JS, Chang TP, Walters MR et al. Time spent at home poststroke: "Home-Time" a meaningful and robust outcome measure for stroke trials.
 Stroke, 2008;39:231-233. DOI:10.1161/STROKEAHA.107.493320.

- 549 14. McDermid I, Barber M, Dennis M, Langhorne P, Macleod MJ, et al. Home-time is a
- feasible and valid stroke outcome measure in national datasets. Stroke 2019;50:00-00.
- 551 Doi:10.1161/StrokeAHA.118.023916.
- 552 15. Fonarow GC, Liang L, Thomas L, Xian Y, Saver JL et al. Assessment of home-time
 553 after acute ischaemic stroke in Medicare beneficiaries. Stroke, 2016:47:836-842.
- 554 DOI:10:1161/STROKEAHA.115.011599
- 555 16. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the Modified Rankin
 556 Scale: a systematic review. Stroke, 2009;40:3393-3395.
- 557 https://doi.org/10.1161/STROKEAHA.109.557256
- 558 17. McArthur K, Beagan MLC, Degnan A, Howarth RC, Mitchell KA, McQuaige FB,
- 559 Shannon MAC, Stott DJ, Quinn TJ. Properties of proxy-derived modified Rankin
- 560 Scale assessments. International Journal of Stroke, 2012; 8;403-407.
- 561 https://doi.org/10.1111/j.1747-4949.2011.00759.x
- 562 18. Worthington JM, Gattellari M, Goumas C, Jalaludin B. Differentiating incident from
- recurrent stroke using administrative data: the impact of varying lengths of look-back
- periods on the risk of misclassification. Neuroepidemiology 2017;48:111-118 doi:
- 565 10.1159/000478016
- 566 19. Gattellari M, Goumas C, Jalaludin B, Worthington J. The impact of disease severity
 adjustment on hospital standardised mortality ratios: Results from a service-wide
- analysis of ischaemic stroke admissions using linked pre-hospital, admissions and
 mortality data. *PLoS ONE* 2019; 14:e0216325.
- 570 https://doi.org/10.1371/journal.pone.0216325
- 571 20. Australian Consortium for Classification Development. International Statistical
- 572 Classification of Diseases and Health Related Problems and Australian Coding
- 573 Standards for International Statistical Classification of Diseases and Related Health

574	Problems. Tenth Revision, Australian Modification, 2015. Independent Pricing
575	Authority (Ninth Edition).
576	21. McCormick N, Bhole V, Lacaille D, Avina-Zubieta JA. Validity of diagnostic codes
577	for acute stroke in administrative databases: a systematic review. PLoS ONE 2015; 10:
578	e0135834. doi:10.1371/journal.pone.0135834
579	22. Hemphill JC, Adeoye OM, Alexander DN, Amin-Hanjani S, Cushman M, George
580	MG, LeRoux PD, Mayer SA, Qureshi AI, Saver JL, Schwamm LH, Sheth KN,
581	Tirschwell D. Clinical performance measures for adults hospitalized with
582	intracerebral haemorrhage: performance measures for healthcare professionals from
583	the American Heart Association/American Stroke Association. Stroke; 49:e243-e261.
584	https://doi.org/10.1161/STR.000000000000171
585	23. Lichtman JH, Jones SB, Leifheit-Limson EC, Wang Y, Goldstein LB. 30-day
586	mortality and readmission after hemorrhagic stroke among Medicare beneficiaries in
587	Joint Commission primary stroke center-certified and noncertified hospitals. Stroke
588	2011;42:3387-3391 doi: 10.1161/STROKEAHA.111.622613
589	24. Bardach NS, Zhao S, Gress DR, Lawton MT, Johnston C. Association between
590	subarachnoid hemorrhage outcomes and number of cases treated at California
591	Hospitals. Stroke, 2002; 33:1851-1856.
592	https://doi.org/10.1161/01.STR.0000019126.43079.7B
593	25. Krumholz HM, Brindis RG, Brush JE, Cohen DJ, Epstein AJ, Furie K, et al.
594	Standards for statistical models used for public reporting of health outcomes. An
595	American Heart Association Scientific Statement from the Quality of Care and
596	Outcomes Research Interdisciplinary Writing Group. Circulation, 2006;113:456-62

597 doi: 10.1161/CIRCULATIONAHA.105.170769

598	26. Weir CJ, Bradford AP, Lees KR. The prognostic value of the components of the
599	Glasgow Coma Scale following acute stroke. QJM, 2003;96:67-74.
600	https://doi.org/10.1093/qjmed/hcg008
601	27. Report of World Federation of Neurological Surgeons Committee on aneurysmal
602	Subarachnoid Hemorrhage Grading Scale. J Neurosurg. 1988;68:985–986
603	28. Fonarow GC, Pan W, Saver JL, Smith EE, Broderick JP et al. Relationship of
604	National Institutes of Health Stroke Scale to 30-day mortality in Medicare
605	Beneficiaries with Acute Ischemic Stroke. JAHA;2012;00:1-9. doi:
606	10.1161/JAHA.111.000034
607	29. Simpson AN, Wilmskoetter J, Hong I, Li, C-Y, Juach EC. Bonilha HS, Anderson K,
608	Harvey J, Simpson KN. Stroke administrative severity index: using administrative
609	data for 30-day post-stroke outcomes prediction. Journal of Comparative
610	Effectiveness Research, 2018;7:2930304.
611	30. Kidd D, Stewart G, Baldry J, Johnson J, Rossiter D et al. The functional independence
612	measure: a comparative validity and reliability study. Disabily Rehabilitation.
613	1995;17:10–14
614	31. Australasian Rehabilitation Outcomes Centre. The Annual AROC Report: the state of
615	Rehabilitation. 2009, 2010, 2011, 2012, 2013.
616	https://ahsri.uow.edu.au/aroc/archivedreports/index.html last accessed July 28, 2019.
617	32. Quan H, Sundararjan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding
618	algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
619	Medical Care 2005;43:1130-9 doi: 10.1097/01.mlr.0000182534.19832.83
620	33. Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charlson Index Comorbidity
621	Adjustment for Ischemic Stroke Outcome Studies. Stroke 2004;35:1941-1945. doi:
622	10.1161/01.STR.0000135225.80898.1c

- 623 34. Australian Bureau of Statistics. Socioeconomic Indexes for Areas (SEIFA). Technical
- 624 Paper 2006. Canberra, Commonwealth of Australia, 2008.:
- 625 http://www.abs.gov.au/ausstats/abs@.nsf/mf/2039.0.55.001/.
- 626 35. Australian Bureau of Statistics. Available from:
- 627 http://www.abs.gov.au/websitedbs/censushome.nsf/home/nonresponseratesLast
- $accessed 28^{th}$ July 2019.
- 629 36. O'Brien EC, Xian Y, Xu H, Wu J, Saver JL, Smith EE, Schwamm LH, Peterson ED,
- 630 Reeves MJ, Bhatt DL, Maisch L, Hannah D, Lindholm B, Olson D, Bettger JP,
- 631 Pencina M, Hernandez AF, Fonarow GC. Hospital variation in home-time after acute
- 632 ischemic stroke: insights from the PROPSER study (Patient-Centred Researcher Into
- 633 Outcomes Stroke Patients Prefer and Effectiveness Research). Stroke 2016;47:2627-
- 634 2633. DOI:10.1161/STROKEAHA.116.013563.
- 635 37. Gall SL, DOnnan G, Dewey HM, Macdonnell R< Sturm J, Gilligan A, Srikanth V,
- 636 Thrift AG. Sex differences in presentation, severity, and management of stroke in a
 637 population-based study. Neurology 2010, 74:975-81.
- 638 doi10.1212/WNL.0b013e3181d5a48f.
- 639 38. Banks JL, Marotta CA. Outcomes validity and reliability of the Modified Rankin
 640 scale: Implications for stroke clinical trials. Stroke, 2007;38:1091-1096.
- 641 https://doi.org/10.1161/01.STR.0000258355.23810.c6Stroke. 2007;38:1091–1096
- 642 39. Mishra NK, Shuaib A, Lyden P, Diener HC, Grotta J, Davis S, Davalos A, Ashwood
- 643 T, Wasiewski W, Lees KR. Home time is extended in patients with ischemic stroke
- 644 who receive thrombolytic therapy: a validation study of home time as an outcome
- 645 measure. Stroke 2011;42:1046-1050. doi: 10.1161/STROKEAHA.110.601302
- 40. Kapoor A, Lanctôt KL, Bayley M, Kiss A, Herrmann N. "Good outcome" isn't good
- 647 enough. Cognitive impairment, depressive symptoms, and social restrictions in

648	physically recovered stroke patients. Stroke, 2017;48:1688-1690.
649	https://doi.org/10.1161/STROKEAHA.117.016728
650	41. Preen DB, Holman CD, SPilsbury K, Semmens JB, Brameld KJ. Length of
651	comorbidity lookback period affected regression model performance of administrative
652	health data. Journal of Clinical Epidemiology 2006; 59:940-6.
653	DOI:10.1016/j.jclinepi.2005.12.013
654	42. Australian Institute of Health and Welfare 2018. Australian Institute of Health and

Welfare Corporate Plan 2018–19 to 2021–22. Cat. no. AUS 224. Canberra: AIHW.

33

656 Supplementary Material

Title: Measuring stroke outcomes using linked administrative data: Population-based
estimates and validation of "home-time" as a surrogate measure of functional status.

660

660		
661	Authors:	
662	Name:	Melina Gattellari ^{*a,b}
663	Email:	melina.gattellari@health.nsw.gov.au
664		
665	Name:	Chris Goumas ^{a,c}
666	Email:	<u>chris.goumas@sydney.edu.au</u>
667		
668	Name:	Bin Jalaludin ^{a,d,e}
669	Email:	<u>bin.jalaludin@health.nsw.gov.au</u>
670		
671	Name:	John Worthington ^{a,b,f}
672	Email:	John.Worthington@health.nsw.gov.au
673		
674	Affiliations:	^a Ingham Institute for Applied Medical Research,
675		1 Campbell Street, Liverpool, NSW, 2170, Australia
676		
677		^b Department of Neurology, Royal Prince Alfred Hospital,
678		Missenden Road, Camperdown, NSW, 2050, Australia.
679		
680		^c University of Sydney, School of Public Health, University of Sydney
681		
682		^d Population Health Intelligence, Healthy People and Places Unit; South
683		Western Sydney Local Health District, Liverpool, Sydney, New South
684		Wales, Australia
685		
686		^e School of Public Health, The University of New South Wales,
687		Kensington, Sydney, New South Wales, Australia
688		
689		^f South Western Sydney Clinical School, The University of New South
690		Wales, Liverpool, Sydney, New South Wales, Australia
691		

692 *Corresponding author.

- Supplementary Table 1: The RECORD statement checklist of items, extended from the STROBE statement, that should be reported
 in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstra	act		-		1
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Title, Abstract	 RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between 	Title (administrative data is specified). Abstract, Line 43. Title; Abstract,
				databases was conducted for the study, this should be clearly stated in the title or abstract.	lines 43-44.
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction, Lines 64-98.		Introduction, Lines 64-98.
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction, Lines 92-98.		

Methods					
Study Design	4	Present key elements of study	Methods, Lines		
		design early in the paper	102-111		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods, Lines 112-120.		
Participants	6	 (a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls 	Not applicable: this is neither a cohort nor a case-control study	RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided. RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was	Methods, lines 112-141. Methods, Lines 115-127; citation to relevant references
		 <i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> - For methods and the studies of the second study - For method at the second study - For method of the second study - For method at the second study - For method study - For methods at the second study - For method study - For methods at the second study - For method study - For methods at the second study - For methods study - For methods at the second s	Not applicable: this is neither a cohort nor a case-control study.	 conducted for this study and not published elsewhere, detailed methods and results should be provided. RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number 	18,19,21,22 Figure 1.
		matched studies, give matching criteria and the number of controls per case		of individuals with linked data at each stage.	

Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	Methods, Lines 142-151 (outcome described); Lines 162-175, incorporating reference 19 describing previous validation; Lines 176 to 185; Lines 203 to 207.	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	Methods, Lines 142-151 (outcome described); Lines 162-175, incorporating reference 19 describing previous validation; Lines 176 to 185; Lines 203 to 207.
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Methods, Lines 142-151 (outcome described); Lines 162-175, incorporating reference 19 describing previous validation; Lines 176 to 185; Lines 203 to 207.		
Bias	9	Describe any efforts to address potential sources of bias	Lines 132 to 141.		
Study size	10	Explain how the study size was arrived at	Methods, line 112 to 114 (all available cases)		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	Methods, Statistical analysis. Lines 186 to 192; Lines 210 to 216.		

Statistical	12	(a) Describe all statistical	Methods, Statistical		
methods		methods, including those used	Analysis, Lines 186		
		to control for confounding	to 217.		
		(b) Describe any methods used	Figure 1.		
		to examine subgroups and			
		interactions			
		(c) Explain how missing data			
		were addressed			
		(d) <i>Cohort study</i> - If applicable,	Not applicable.		
		explain how loss to follow-up			
		was addressed			
		<i>Case-control study</i> - If	Not applicable		
		applicable, explain how			
		matching of cases and controls			
		was addressed			
		Cross-sectional study - If	Not applicable		
		applicable, describe analytical			
		methods taking account of			
		sampling strategy			
		(e) Describe any sensitivity	e) Lines 189-192.		
		analyses			
Data access and				RECORD 12.1: Authors should	Methods, Line
cleaning				describe the extent to which the	104 to 111.
methods				investigators had access to the	Data statement,
				database population used to create the	Lines 499 to 503.
				study population.	
				RECORD 12.2: Authors should	Methods, Line
				provide information on the data	
				cleaning methods used in the study.	
Linkage				RECORD 12.3: State whether the	Figure 1,
				study included person-level,	Lines 105 to 111.

Results				institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	
Participants	13	 (a) Report the numbers of individuals at each stage of the study (<i>e.g.</i>, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non- participation at each stage. (c) Consider use of a flow diagram 	a) Figure 1. b) Lines 222 to 228. c) Figure 1.	RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Figure 1, Lines 112 t o136.
Descriptive data	14	 (a) Give characteristics of study participants (<i>e.g.</i>, demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i>, average and total amount) 	 a) Supplementary Tables 2-5. b) Figure 1, Supplementary Tables 2-5. c) Not applicable 		
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time	Tables 1 and 2.		

		<i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or			
Main results	16	 (a) Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period 	Tables 1 to 3. Supplementary Tables 2 to 5.		
Other analyses	17	Report other analyses done— e.g., analyses of subgroups and interactions, and sensitivity analyses	Tables 1 to 3 (removing patients who died in hospital).		
Discussion					
Key results	18	Summarise key results with reference to study objectives	Lines 361 to 405.		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	Lines 419 to 460	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include	Lines 426 to 460. Lines 461 to 480.

		Discuss both direction and		discussion of misclassification bias,	
		magnitude of any potential bias		unmeasured confounding, missing	
				data, and changing eligibility over	
				time, as they pertain to the study	
				being reported.	
Interpretation	20	Give a cautious overall	Discussion.		
		interpretation of results			
		considering objectives,			
		limitations, multiplicity of			
		analyses, results from similar			
		studies, and other relevant			
		evidence			
Generalisability	21	Discuss the generalisability	Lines 406 to 418;		
		(external validity) of the study	461 to 480.		
		results			
Other Information	on		-		-
Funding	22	Give the source of funding and	Lines 487 to 492.		
		the role of the funders for the			
		present study and, if applicable,			
		for the original study on which			
		the present article is based			
Accessibility of				RECORD 22.1: Authors should	Lines 499 to 504.
protocol, raw				provide information on how to access	
data, and				any supplemental information such as	
programming				the study protocol, raw data, or	
code				programming code.	

696

⁶⁹⁷ *Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD

698 Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS*

699 *Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution (<u>CC BY</u>) license.

Characteristics	N	%
Sub-type		
Ischaemic Stroke	57,949	77.8
Intracerebral Haemorrhage	12,192	16.4
Subarachnoid Haemorrhage	4,360	5.9
Sex		
Male	37,404	50.2
Female	37,097	49.8
Age at diagnosis (years)		
<50	5,205	7.0
50-64	11,520	15.5
65-74	14,692	19.7
75-84	24,731	33.2
85+	18,353	24.6
Stroke Severity (IS and ICH); N=70,141**		
Ambulant	23,751	33.9
GCS score=15	25,429	36.3
GCS score=13-14	9,001	12.8
GCS score=9-12	7,219	10.3
GCS score=3-8	4,215	6.0
Missing*	526	0.7
Stroke Severity (SAH);		
N=4,360**		
Ambulant	1,600	36.7
GCS score=15	1,297	29.7
GCS score=13-14	392	9.0
GCS score=7-12	459	10.5
GCS score=3-6	585	13.4
Missing*	27	0.6

.. AT #4 501) C 702

*Patients arriving by ambulance with missing GCS (Glasgow Coma Scale) scores **Denominator used for calculation of percentages 703

43

Supplementary Table 3: Adjusted* mean days spent at home: Ischaemic Stroke (n=56,445)*

N (11-30, 44 3)	NT	M (050/ CI)	D 1
Variable	N	Mean (95% CI)	P-valu
Age (years; quadratic effect)	56.445	-	< 0.002
Sex	00,110		
Males	28,952	41 (41-42)	
Females	27,493	41 (40-41)	0.02
Year			
2005	6,563	38 (37-39)	
2006	6,266	41 (39-42)	
2007	6,094	41 (40-43)	
2008	6,119	41 (40-42)	
2009	5,992	41 (40-43)	
2010	5,787	42 (41-44)	
2011	6,041	41 (39-42)	
2012	6,157	41 (40-42)	
2013	6,053	43 (41-44)	
2014	1,373	42 (40-44)	< 0.00
SES (IRSD)*			
Q1 (lowest)	13,420	41 (39-42)	
Q2	11,429	40 (39-41)	
Q3	11,302	41 (39-42)	
Q4	9,760	41 (40-43)	
Q5 (highest)	10,534	42 (41-43)	0.05
Marital status			
Married/de facto	28,526	43 (42-43)	
Other	27,919	39 (38-40)	< 0.00
Previous stroke			
No	53,007	41 (40-42)	
Yes	3,438	43 (41-44)	0.07
Stroke severity			
Ambulant	20,036	51 (50-52)	
GCS score=15	21,416	46 (45-47)	
GCS score=13-14	7,056	36 (35-38)	
GCS score=9-12	5,498	23 (22-24)	
GCS score=3-8	2,439	12 (11-14)	< 0.001

Variable	Ν	Mean (95% CI)	P-value
Charlson Comorbidities*			
Myocardial infarction			
No	49,429	42 (41-42)	
Yes	7,016	37 (36-38)	< 0.001
Congestive heart failure			
No	47,579	42 (42-43)	
Yes	8,866	34 (33-35)	< 0.001
Peripheral vascular disease			
No	51,315	41 (40-42)	
Yes	5,130	39 (37-40)	< 0.001
Dementia			
No	50,060	43 (42-43)	
Yes	6,385	31 (29-32)	< 0.001
Chromic pulmonary disease			
No	50,590	41 (40-42)	
Yes	5,855	39 (38-41)	0.002
Connective tissue disease			
No	55,382	41 (40-42)	
Yes	1,063	39 (37-42)	0.12
Peptic ulcer			
No	55,040	41 (40-42)	
Yes	1,405	36 (34-38)	< 0.001

55,589	41 (40-42)	
856	38 (36-40)	0.01
5		
47,436	41 (40-42)	
9,009	40 (38-41)	0.01
45,663	41 (40-42)	
10,782	40 (39-41)	0.001
49,977	42 (41-42)	
6,468	36 (35-38)	< 0.001
	55,589 856 47,436 9,009 45,663 10,782 49,977 6,468	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

45

Variable	Ν	Mean (95% CI)	P-value
Non-metastatic malignancy			
No	51,775	41 (40-42)	
Yes	4,670	38 (37-40)	< 0.001
Moderate/severe liver disease			
No	56,179	41 (40-42)	
Yes	266	30 (26-36)	< 0.001
Metastatic malignancy			
No	54,925	41 (41-42)	
Yes	1,520	27 (25-30)	< 0.001

*Adjusted for all other variables in table and days spent in hospital in the 12 months before the

stroke admission. Analyses adjusted for interdependencies of data due to clustering of cases within
 hospitals. Complete case analysis undertaken; excludes 1,504 (2.6%) cases with missing covariate
 data.

**SES=socioeconomic status measured using IRSD=Index of Relative Socio-economic

712 Disadvantage³⁴

⁷¹³ [†]Charlson comorbidities excluded cerebrovascular diseases and hemiplegia as redundant following

example of Goldstein et al^{33} ; HIV/AIDs was also given low prevalence.

46

Variable	N	Mean (95% CI)	P-valu
Age (quadratic)			< 0.00
Sex			
Males	5.888	21 (20-22)	
Females	5,905	21 (20-22)	0.89
Year			
2005	1,284	17 (15-19)	
2006	1,355	21 (19-24)	
2007	1,188	20 (18-23)	
2008	1,285	23 (21-25)	
2009	1,265	22 (20-25)	
2010	1,267	23 (20-25)	
2011	1,294	21 (19-24)	
2012	1,295	20 (18-22)	
2013	1,261	20 (19-23)	
2014	299	18 (15-22)	< 0.00
SES (IRSD)**			
Q1 (lowest)	2,846	21 (19-23)	
Q2	2,217	21 (19-23)	
Q3	2,259	21 (20-23)	
Q4	2,062	20 (18-22)	
Q5 (highest)	2,409	21 (19-23)	0.85
Marital status			
Married/de facto	6,360	21 (20-22)	
Other	5,433	21 (19-22)	0.53
Previous stroke			
No	10,590	21 (20-22)	
Yes	1,203	22 (20-25)	0.28
Stroke severity			
Ambulant	3,265	38 (36-40)	
GCS score=15	3,615	31 (30-33)	
GCS score=13-14	1,744	23 (21-24)	
GCS score=9-12	1,524	11 (10-13)	
GCS score=3-8	1,645	4 (3-5)	< 0.00

715 Supplementary Table 4: Adjusted* mean days spent at home: ICH

Variable	N	Mean (95% CI)	P-value
Charlson Comorbidities†		X /	
Myocardial infarction			
No	10,693	21 (20-22)	
Yes	1,100	18 (15-20)	0.006
Congestive heart failure			
No	10.530	21 (20-22)	
Yes	1,263	17 (14-20)	0.007
Peripheral vascular disease			
No	10.926	21 (20-22)	
Yes	867	18 (16-20)	0.01
Dementia			
No	10.361	21 (20-22)	
Yes	1,432	19 (16-23)	0.42
Chromic pulmonary disease			
No	10,741	21 (20-22)	
Yes	1,052	20 (17-23)	0.50
Connective tissue disease			
No	11,596	21 (20-22)	
Yes	197	20 (14-28)	0.81
Peptic ulcer			
No	11,510	21 (20-22)	
Yes	283	22 (17-30)	0.60
Mild liver disease			
No	11,418	21 (20-22)	
Yes	375	20 (14-27)	0.70
Diabetes without complications			
No	10,251	20 (19-21)	
Yes	1,542	23 (21-26)	0.03
Diabetes with complications			
No	9,986	21 (20-22)	
Yes	1,807	20 (18-23)	0.74
Renal disease			
No	10,621	21 (20-22)	
Yes	1,172	18 (15-21)	0.05

48

Variable	Ν	Mean (95% CI)	P-value
Non-metastatic malignancy			
No	10,750	21 (20-22)	
Yes	1,043	17 (15-19)	< 0.001
Moderate/severe liver disease			
No	11,636	21 (20-22)	
Yes	157	17 (11-27)	0.35
Metastatic malignancy			
No	11,531	21 (20-22)	
Yes	262	27 (19-38)	0.16

*Adjusted for all other variables in table and days spent in hospital in the 12 months before the

stroke admission. Analyses adjusted for interdependencies of data due to clustering of cases within
 hospitals. Complete case analysis undertaken; excludes 399 (3.3%) cases with missing covariate

720 data.

**SES=socioeconomic status measured using IRSD=Index of Relative Socio-economic

722 Disadvantage³⁴

⁷²³ [†]Charlson comorbidities excluded cerebrovascular diseases and hemiplegia as redundant following

example of Goldstein et al;³³ HIV/AIDs was also excluded given low prevalence.

Variable	Ν	Mean (95% CI)	P-valu
Age (quadratic)		· · · · · · · · · · · · · · · · · · ·	< 0.00
Sex			
Males	1,644	31 (29-33)	
Females	2,578	30 (29-32)	0.38
Year			
2005	401	25 (22-29)	
2006	438	31 (26-36)	
2007	446	31 (27-35)	
2008	476	33 (30-37)	
2009	464	30 (26-34)	
2010	430	30 (27-34)	
2011	476	29 (26-32)	
2012	479	32 (29-35)	
2013	489	33 (29-38)	
2014	123	30 (23-39)	0.04
SES (IRSD)**			
Q1 (lowest)	929	32 (28-36)	
Q2	709	30 (27-34)	
Q3	842	31 (28-35)	
Q4	839	29 (27-31)	
Q5 (highest)	903	30 (27-33)	0.53
Marital status			
Married/de facto	2,553	32 (30-34)	
Other	1,669	28 (27-30)	0.02
Previous stroke			
No	4,035	30 (29-32)	
Yes	187	40 (32-49)	0.02
Stroke severity			
Ambulant	1,562	47 (44-50)	
GCS score=15	1,277	45 (43-47)	
GCS score=13-14	380	29 (25-33)	
GCS score=9-12	446	15 (12-18)	
GCS score=3-8	557	7 (5-9)	< 0.00

Variable	N	Mean (95% CI)	P-value
Charlson Comorbidities†		, /	
Myocardial infarction			
No	4,007	31 (29-32)	
Yes	215	25 (20-32)	0.12
Congestive heart failure			
No	3,958	31 (29-32)	
Yes	264	28 (21-36)	0.48
Peripheral vascular disease			
No	4,010	31 (29-32)	
Yes	212	30 (22-41)	0.88
Dementia			
No	4,080	30 (29-32)	
Yes	142	31 (21-48)	0.89
Chromic pulmonary disease			
No	3,976	31 (30-32)	
Yes	246	25 (19-32)	0.09
Connective tissue disease			
No	4,169	30 (29-32)	
Yes	53	38 (29-50)	0.11
Peptic ulcer			
No	4,165	31 (29-32)	
Yes	57	24 (17-35)	0.21
Mild liver disease			
No	4,142	31 (29-32)	
Yes	80	30 (21-42)	0.93
Diabetes without complications			
No	3,955	30 (29-32)	
Yes	267	36 (28-47)	0.15
Diabetes with complications			
No	3,901	31 (29-32)	
Yes	321	28 (23-35)	0.53
Renal disease			
No	4,054	31 (29-32)	
Yes	168	23 (18-29)	0.03

51

Variable	Ν	Mean (95% CI)	P-value
Non-metastatic malignancy			
No	4,041	31 (29-32)	
Yes	181	28 (21-36)	0.46
Moderate/severe liver disease			
No	4,196	31 (29-32)	
Yes	26	16 (8-29)	0.03
Metastatic malignancy			
No	4,165	30 (29-32)	
Yes	57	33 (22-49)	0.69

*Adjusted for all other variables in table and days spent in hospital in the 12 months before the

stroke admission. Analyses adjusted for interdependencies of data due to clustering of cases within
 hospitals. Complete case analysis undertaken; excludes 138 (3.2%) cases with missing covariate

data.

730 **SES=socioeconomic status measured using IRSD=Index of Relative Socio-economic

731 Disadvantage³⁴

732 [†]Charlson comorbidities excluded cerebrovascular diseases and hemiplegia as redundant following

example of Goldstein et al;³³ HIV/AIDs was also excluded given low prevalence.